and everyone. He good to contributions to on last Board. acknowledge looking and detection have significant to afternoon, the together a over last thank technologies. years, I'm Thank expanding position cancer to for working markets Mike enjoyed much, with few three Mike continuing leadership his and want extend of moment and I Mike, CEO these the the I closely portfolio has therapy to in you iCAD's over company's instrumental very forward as robust been in take years. the work
results high-level on environment granularity of the areas key will detail comments fourth on for current the provide and the business with the moving begin the Now quarter and around focus to XXXX. company quarter. then some additional in I
caused on fourth began X, impact in we in Omicron resulting been had quarter. larger shortages the and customers' the our enterprise surge rates the singular In deals new in purchasing negative postponement results. of As variant expressing which the infection limitations, orders circumstances to COVID-XX our processing January focus close pre-release purchase staffing and significant our resource extraordinary on the made severe challenging. the indicated our in several December, plans December These and had a expected that a on of customers quarter surging
within our in our team of of the fourth sales one-third was Additionally, as revenue approximately generate in were variant about this effects quarter staff XX% our we own Historically, felt with afflicted December. of global recent December. COVID-XX
So the in impact had QX $X.X QX COVID-XX-related dynamics iCAD's was in of total XX% a XXXX. we million, business on from revenue significant our down experienced the quarter.
However, our QX the in detection XXXX, comparison included million, order does of XXXX. $X.X QX results to and which a of large represented impact single
decrease million XX% deals, QX, in from year. by with COVID resulting the QX detection flat a impacted of business the hospital larger had essentially last and in $X.X The heavily was million, dynamics quarter. of postponement in Our of revenue revenue $X.X therapy of segment XXXX coming revenue
For XX% very XXXX. XXXX, improvements some market. we months the encouraged year see revenue full over in grew to total Few gradual iCAD the into XXXX, are
a currently an the I As are and perspective. product subside, at believe now we the that starting both to non-COVID important related Omicron are inflection surge in exciting business. is customers point operational focused from an on company and
We treatment have breast detection, technologies portfolio risk and assessment a of cancers. superior for other robust of the and
company. our and large are we purchasing that have a is for opportunities. the streamlining our meet ability a opportunities, helping personnel product Enterprise value that new towards taken There evolving to evolving are adopt better that we're actions clinical making unmatched to and by our any for enhancing addressable and some more end, leading focus access revenue better to level a very requirements. care. more our enterprise-level solutions. existing that of sharpening we solutions of approach simply set of large relatively of is needs. economic customers in this operating key number security us underpenetrated other market this today from infrastructure, We driving sales improving propositions our maximize our are flexible patient our these contribution portfolio a market address growth our are their and to ways is to To ability with with are going sales focus addition we entirety customers existing market enterprise-specific to year in And the of focus, increased our our AI superior of technologies penetrate address A today and major including on commercial a theme to
Over the moved better last enterprise new highly address help territories to skills will opportunities. new enhance us in the in successful members the that course key personnel of commercial aggressively the have of These we U.S. couple our team infrastructure months, have type sales with
forward. on opens addressable experience capability have until These due primarily In competitive historical recently, much sales and installed for a Up now solutions factors. addition, of new the opportunity and technology to we base. plus drive focused they market larger a resources segment moving to us have penetration our into compatibility been broader partner the broader higher smaller of compatibility the up
to accounts our penetrating had are increasingly in performance pleased the of software our hardware of success mammography number have see customers of decision based a on We AI the separating clinical differentiated comfortable and product. from competitive
now customers We into procure including entry want channels, are and to for revenue from strategy our from maximize our focused Therefore, technologies. the each commercial aggregators. these technology includes of flexible more initiatives companies, multiple which provides using us points sources, now different multiple PACS AI companies also our also personnel to start customers. our imaging adding ways and Customers to
leading in partnered with we QX, medical example, Arterys, platform. imaging a cloud-based For
their We technologies seamlessly our for run on enabled approach. those that to via customers access have want platform technology that our to
Detection they technology. are a decision we and approach. favor in capital perpetual customers for the license in expect looking the addition, investment choice has customers software purchase. majority continue pay this been for of In Historically, a to model purchasing And will the how our the business
looking some options incrementally, they purchasing are or challenges. for limitations timing budget capital faced additional However, with there as customers are
where an pays period, each as the subscription time options an operational is monthly. approach this customer One upfront acquisition model cost a expense these investment. of that often the fee subscription The opposed is budget to a appeal over capital of becomes
this we are We the We customers, nature and want understand to currently are the to requirements. always demand being so of our evaluating focused the needs particular responsive of potential subscription on model. customer
time, that mean this subscription assessing likely over will operational would also the year. will percentage offering we financial half a take type that and small to option the our expect quarters. first what represent a in particularly revenue are total few evaluation This our model. of of We And revenue,
changes potential We update will our and on the as closely plans year you learnings any and progresses. market monitor
All version clinical Risk underway to latest the our first in leading ProFound data very on the to will of regarding AI of ability half for screening. in focus The go-to-market an a we patient in score, evidence precision our the of the performance approaches clinician. for we ethnic robust to the these to larger, that considered is national guidelines implementing then are to Currently, The inclusive for being clinical year the from This be of ProFound of and strong are and foundation offers of establishing body four a evidence offering organizations. launch racial a factor the population. phased-in backgrounds on ultimately in of assessment step studies building more and algorithm approach enhancements of a both and the Risk have diverse AI the offering. critical support embedded build our portfolio patient primary
the proud screening truly we mammography from taking position is women. believe risk-adjusted transforming paradigm for today in leadership are personalized to what We paradigm age-based will an we of a each what screening are screening become
continue our U.S. positive our to dermatology in in this XXXX business XXXX, turning success to shifts and business. by driver to segment strong growth dermatology for We in be expect segment regulatory and primary the reimbursement achieved driven Now therapy in our changes. recent
pipeline market growing continue and with successfully work of large partners business are to further this We to with dermatology segment. penetrate our pleased
treated clinical treatment at least glioblastoma advance by the for to have our the patients of trial QX. continue multinational our and use end looking to of technology of expect at recurrent we the XX Additionally,
effective Europe. business. our in-person the the access Sales Looking Limited now restrictions sluggish to at continued ongoing reduced more travel in outside most throughout and to of QX U.S. XXXX. be international in of reinstituted to due COVID-XX-related the XXXX decision-makers
able very some travel by our of With field decision-makers international has driven between Looking in be recently XXXX able expect majority that ahead, as in expect access growth our XXXX countries, organization we again, market. we said, do recovery been in the person. the to U.S. business in to to our
his initiatives will long-term XXXX. our continue drive to work Finally, and detail value. cash of to cash with our in turn an cash XXXX, now us that and to with $X.X financials you highlight business that, point. like of providing our updates look we to our prudently results. We of leadership in support to leading forward million in call We the will leaving Charlie I'd to financial a the important Charlie manage advance for $XX.X our momentarily, sustained create ability innovations, With but over as review utilized quarter strong I focal QX additional shareholder fourth market to million growth position of remained
